Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Aerie CEO Anido Talks War Rooms, FDA, Rhopressa, Roclatan, and Getting Along with the Neighbors

    Aerie CEO Anido Talks War Rooms, FDA, Rhopressa, Roclatan, and Getting Along with the Neighbors

    FromOIS Podcast | Ophthalmology's leading Podcast

    Start listeningView podcast show

    Aerie CEO Anido Talks War Rooms, FDA, Rhopressa, Roclatan, and Getting Along with the Neighbors

    FromOIS Podcast | Ophthalmology's leading Podcast

    ratings:
    Length:
    33 minutes
    Released:
    Oct 25, 2017
    Format:
    Podcast episode

    Description

    Aerie Pharmaceuticals scored an impressive win at the recent FDA advisory panel, getting a thumbs up for the approval of Rhopressa. In this interview, CEO Vince Anido explains how Aerie plans to move forward with its lead glaucoma product. He also tells how its new drug-delivery technology will fit into its plans. In addition, we get an update on the late-stage trials of Roclatan.
    Released:
    Oct 25, 2017
    Format:
    Podcast episode

    Titles in the series (100)

    Welcome to the Ophthalmology Innovation Podcast Where you get Candid Conversations with the Leaders and Drivers of Ophthalmic Innovation. OIS is the Largest and Original Producer of World-Class Ophthalmology Innovation Conferences and Content Since 2009.